Structure Therapeutics Inc., a clinical-stage biopharmaceutical company based in San Francisco, has announced the initiation of a first-in-human Phase 1 clinical study for its lead oral small molecule therapy, ACCG-2671. This new treatment aims to target obesity through an innovative approach, leveraging the benefits of amylin receptor agonism. The announcement was made on December 17, 2025.
The clinical study will evaluate the safety and efficacy of ACCG-2671, which is designed to be taken orally once daily. Developed using Structure Therapeutics’ advanced structure-based drug discovery platform, the molecule aims to improve patient access and scalability in the treatment of metabolic diseases, particularly obesity.
Potential Impact of ACCG-2671
According to Xichen Lin, Ph.D., Chief Scientific Officer of Structure Therapeutics, “We believe amylin-based therapies are poised to become an important next-generation component of the treatment landscape for obesity and related conditions.” He emphasized that the company’s unique drug discovery platform has facilitated the efficient progression of ACCG-2671 into clinical trials, positioning it as the most advanced oral small molecule amylin therapy in development.
Preclinical studies have indicated that ACCG-2671 demonstrates significant target engagement and robust weight loss as a standalone treatment. Moreover, when combined with a glucagon-like-peptide receptor agonist (GLP-1 RA), the results suggest enhanced weight loss effects. The therapy has shown a favorable safety profile and pharmacokinetics suitable for once-daily dosing, which could enhance adherence among patients.
A New Approach to Obesity Treatment
The launch of the Phase 1 clinical study represents a significant step in the search for effective obesity therapies. With obesity rates rising globally, the demand for innovative treatment options continues to grow. ACCG-2671 may provide a differentiated backbone therapy that can be used alone or in combination with existing weight loss medications.
Structure Therapeutics aims to address the challenges associated with obesity treatment, which often requires long-term management strategies. By focusing on the metabolic benefits of amylin biology, the company hopes to offer a new solution that not only targets weight loss but also supports overall metabolic health.
As the clinical study progresses, the pharmaceutical community will closely monitor the outcomes of ACCG-2671, which could potentially reshape the treatment landscape for obesity and related metabolic disorders.
